In silico SARS-CoV-2 vaccine development for Omicron strain using reverse vaccinology.

ABSTRACT:

Background

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic began in 2019 but it remains as a serious threat today. To reduce and prevent spread of the virus, multiple vaccines have been developed. Despite the efforts in developing vaccines, Omicron strain of the virus has recently been designated as a variant of concern (VOC) by the World Health Organization (WHO).

Objective

To develop a vaccine candidate against Omicron strain (B.1.1.529, BA.1) of the SARS-CoV-19.

Methods

We applied reverse vaccinology methods for BA.1 and BA.2 as the vaccine target and a control, respectively. First, we predicted MHC I, MHC II and B cell epitopes based on their viral genome sequences. Second, after estimation of antigenicity, allergenicity and toxicity, a v

SUBMITTER: Li V 

PROVIDER: S-EPMC9166176 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature